Uncategorized

BaltTech begins monthly tech survey // Baltimore BioWorks applies for minority business certification // BetaPunch unveils new home page [Startup Roundup]

This is the Startup Roundup. Every Wednesday morning, Technically Baltimore will put together the smaller pieces that make up our startup ecosystem. Gus Sentementes, the BaltTech blogger for the Baltimore Sun, has begun a monthly survey where he asks tech companies in Maryland a different question). For the inaugural survey, he asked tech companies what the “number […]

This is the Startup Roundup. Every Wednesday morning, Technically Baltimore will put together the smaller pieces that make up our startup ecosystem.
Gus Sentementes, the BaltTech blogger for the Baltimore Sun, has begun a monthly survey where he asks tech companies in Maryland a different question). For the inaugural survey, he asked tech companies what the “number one issue they face right now.” Responses came from such companies as Mindgrub Technologies and Bizelo (common themes were capital and recruiting). Sentementes has also been collecting information on tech companies in Maryland using a publicly available Google Spreadsheet.

Baltimore BioWorks, which moved into office space at the University of Maryland BioPark’s BioInnovation Center earlier this month, is now applying for “state certification as a Minority Business Enterprise that would allow the life sciences manufacturing and training firm to bid on state contracts that set aside a slice of business for minority- and women-owned companies,” reports Bmore Media. Next month, BioWorks plans to open a 14,000-square-foot production facility.
BetaPunch, the website that connects other startups with beta testers that Technically Baltimore covered yesterday, unveiled a new home page Tuesday. According to the BetaPunch site, more than 250 startups have used the service to recruit beta testers.
Biotech firm Gliknik Inc., founded in 2007 and located in the city’s Hollins Market neighborhood just nearby the University of Maryland BioPark, has $4.8 million committed of a $15 million planned round, according to SEC filings. Gliknik develops “new therapies for patients with cancer and autoimmune/inflammatory diseases,” according to its website.

Companies: BetaPunch

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

Our services Preferred partners The journalism fund
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

Here's what to consider before asking an AI app for sexual health help

15 virtual and in-person tech community events for September

Baltimore startup aims to be ‘FedEx for space,’ shipping cargo into orbit faster and cheaper

Why entrepreneurship is booming in the US Southeast

Technically Media